The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or ...

Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redef.

Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. Antares is a spin ...

The startup and its management come from Scorpion Therapeutics. Lilly’s acquisition of Scorpion closed in March, a deal that committed up to $2.5 billion for that biotech’s most advanced ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The ...

Antares Therapeutics has launched with $177 million in series A financing and a staff already at full speed, according to CEO Adam Friedman. The company is a spin-off of Scorpion Therapeutics, which ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

—Antares Therapeutics revealed $177 million in financing to support a preclinical pipeline of assets from Scorpion Therapeutics. Eli Lilly acquired Scorpion earlier this year to get one drug, a ...